Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 500Ton/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Rivaroxaban (CAS: 366789-02-8)
Item | Index |
Molecular Formula | C19H18ClN3O5S |
Molecular Weight | 435.88 |
Specification | CP/USP/EP |
Content | 99%min |
Basic Information
Rivaroxaban (BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is an orally activedirect factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8 to 12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
There is currently no specific way to reverse the anticoagulant effect of rivaroxaban in the event of a major bleeding event, unlike warfarin.
Medical uses
Rivaroxaban can be used to prevent strokes in those with atrial fibrillation due to causes other than heart valvedisease, and at least one additional risk factor for stroke (congestive heart failure, hypertension, age, diabetes, and prior stroke)
Rivaroxaban can also be used to prevent the formation of blood clots in the veins (deep venous thrombosis) in adults who have had an operation to replace a hip or knee and for treatment and prevention of acute deep venous thrombosisin adults. It can not be used for prevention of venous thrombosis in hospitalized medically ill patients.
Rivaroxaban is not indicated for prosthetic heart valves or for mitral stenosis.
